睿昂基因(688217) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥71,252,925.52, a decrease of 28.53% compared to the same period last year[5] - The net profit attributable to shareholders for Q3 2023 was ¥2,593,555.12, down 83.09% year-on-year[5] - The basic earnings per share for Q3 2023 was ¥0.05, reflecting a decline of 82.14% compared to the same period last year[6] - The net profit attributable to shareholders for the year-to-date period was ¥18,829,092.35, down 48.58% year-on-year[5] - Total revenue for the first three quarters of 2023 was ¥198,819,318.04, a decrease of 27.0% compared to ¥272,407,214.95 in the same period of 2022[22] - Operating profit for Q3 2023 was ¥11,794,507.29, down 76.2% from ¥49,462,906.22 in Q3 2022[23] - Net profit for Q3 2023 was ¥11,068,737.28, a decline of 74.7% compared to ¥43,779,410.06 in Q3 2022[23] Research and Development - The R&D investment totaled ¥19,043,175.47 in Q3 2023, accounting for 26.73% of operating revenue, an increase of 8.67 percentage points from the previous year[6] - Research and development expenses for Q3 2023 were ¥50,370,816.26, up 3.7% from ¥48,473,757.51 in Q3 2022, indicating continued investment in innovation[23] Assets and Liabilities - The total assets at the end of Q3 2023 were ¥1,074,510,496.93, a slight decrease of 0.78% from the end of the previous year[6] - The total current assets as of September 30, 2023, amounted to ¥548,649,551.64, a decrease from ¥624,479,327.42 at the end of 2022, representing a decline of approximately 12.14%[18] - Total liabilities decreased to ¥81,452,652.22 in Q3 2023 from ¥111,500,983.32 in Q3 2022, representing a reduction of 26.9%[20] - The company's cash and cash equivalents showed a significant increase, with short-term borrowings reduced to ¥749,660.00 from ¥1,348,157.84 year-over-year[20] Cash Flow - The cash flow from operating activities for the year-to-date period was ¥29,403,994.54, indicating a recovery in cash collection compared to the previous year[6] - Net cash flow from operating activities for the first three quarters of 2023 was CNY 29,403,994.54, significantly up from CNY 1,785,062.59 in the same period of 2022[25] - Total cash inflow from operating activities was CNY 275,590,871.40, compared to CNY 227,841,010.25 in the previous year[25] - Cash outflow from operating activities totaled CNY 246,186,876.86, an increase from CNY 226,055,947.66 year-over-year[25] - Cash flow from investment activities showed a net outflow of CNY 120,794,899.36, contrasting with a net inflow of CNY 62,361,802.96 in the same period last year[26] - Cash inflow from financing activities was CNY 28,969,781.49, a significant increase from CNY 596,995.94 in Q3 2022[26] - The net cash increase for the period was CNY -64,058,029.97, compared to an increase of CNY 70,417,958.54 in the previous year[26] - The ending cash and cash equivalents balance was CNY 139,107,090.06, down from CNY 193,323,002.50 at the end of Q3 2022[26] Equity and Investments - The equity attributable to shareholders of the parent company rose to ¥966,172,282.92 in Q3 2023 from ¥936,895,942.58 in Q3 2022, an increase of 3.1%[20] - The company holds other equity instrument investments totaling ¥71,763,354.76, an increase from ¥56,763,354.76, which is a growth of approximately 26.39%[18] Market and Business Developments - The company reported a 26.88% increase in tumor-related business revenue compared to the same period last year, despite a decline in overall testing business revenue[11] - The company experienced a significant decline in net profit due to a drop in testing revenue, impacting both the current and year-to-date periods[11] - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[17] - There are no significant mergers or acquisitions reported in the current quarter[17]